DK1957647T3 - Immunstimulerende oligoribonukleotider - Google Patents
Immunstimulerende oligoribonukleotider Download PDFInfo
- Publication number
- DK1957647T3 DK1957647T3 DK06838257T DK06838257T DK1957647T3 DK 1957647 T3 DK1957647 T3 DK 1957647T3 DK 06838257 T DK06838257 T DK 06838257T DK 06838257 T DK06838257 T DK 06838257T DK 1957647 T3 DK1957647 T3 DK 1957647T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- orn
- immunostimulatory
- rna
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (9)
1. Fremgangsmåde til stimulering af en produktion af et pro-inflammatorisk cytokin udvalgt fra TNF-alfa og IL-12, hvilken fremgangsmåde omfatter: at bringe en TLR8-eksprimerende celle in vitro i kontakt med et RNA-oligonukleotid (ORN) omfattende: N-U-R-1-R2, hvor N er et ribonukleotid, og N ikke indeholder et U, U er uracil eller et derivat deraf, og R er et ribonukleotid, hvor mindst et af Ri og R2 er adenosin (A) eller cytosin (C) eller derivater deraf, og hvor R ikke er U, medmindre N-U-R1-R2 indeholder mindst to A, hvor ORN'et er udvalgt fra: GCCACCGAGCCGAAUAUACC SEQ ID NO: 11; AUAUAUAUAUAUAUAUAUAU SEQ ID NO:12; UUAUUAUUAUUAUUAUUAUU SEQ ID NO:13; AAUAAUAAUAAUAAUAAUAA SEQ ID NO:16; AAAUAAAUAAAUAAAUAAAU SEQ ID NO: 17; AAAAUAAAAUAAAAUAAAAU SEQ ID NO:18; CUACUACUACUACUACUACU SEQ ID NO:24; UUAUUAU SEQ ID NO:30; UAUAUAU SEQ ID NO:33; CCGAGCCGCAUAUCCC SEQ ID NO:36; CCGAGCCGCUAUACCC SEQ ID NO:37; CCGAGCCAUAUAUCCC SEQ ID NO:38; CCGAGCCAUAUAUAUC SEQ ID NO:39; CCGAGCCGAAUAACCC SEQ ID NO:40; CCGAGCCGCAUAACCC SEQ ID NO:41; CCGAGCCGAAUACCCC SEQ ID NO:42; CCGAGCCGCCUAACCC SEQ ID NO:43; CCGAGCCGAAUCCCCC SEQ ID NO:44; CCGAGCCGCAUACCCC SEQ ID NO:45; CCGAGCCGCAUCCCCC SEQ ID NO:46; CCGAGCCGCCUACCCC SEQ ID NO:47; CCGAGCCGCAUUACCC SEQ ID NO:48; CCGAGCCGCUAUCCCC SEQ ID NO:55; CCGAGCCGAAUGUACC SEQ ID NO:63; CCGAGCCGAUAUUACC SEQ ID NO:65; CCGAGCCGAAGGUACC SEQ ID NO:82; CCGAGCCGAAGGUGCC SEQ ID NO:83; CCGAGCCGAAGCUCCC SEQ ID NO:84; CCGAGCCGAAGAUACC SEQ ID NO:85; CCGAGCCGAAGCUACC SEQ ID NO:87; og CCGAGCCGAAGCUGCC SEQ ID NO:88; hvor ORN'et eventuelt indeholder mindst en backbone-modifikation; i en virksom mængde til stimulering af en pro-inflammatorisk cytokinprodukti- on, og hvor ingen væsentlig IFN-a-produktion induceres som reaktion på ORN'et i forhold til baggrunden; og endvidere hvor ORN'et er komplekseret til N-[1-(2,3-dioleoyloxy)propyl]-N,N,Ntrimethylammoniummethyl-sulfat (DOTAP).
2. Fremgangsmåde ifølge krav 1, hvorved en IFN-a-produktion som reaktion på ORN'et er mindre end 300 pg/ml.
3. RNA-oligonukleotid (ORN) omfattende: N-U-Ri-R2, hvor N er et ribonu-kleotid, og N ikke indeholder et U, U er uracil eller et derivat deraf, og R er et ribonukleotid, hvor mindst et af Ri og R2 er adenosin (A) eller cytosin (C) eller derivater deraf, og hvor R ikke er U, medmindre N-U-RrR2 indeholder mindst to A, hvor ORN'et er udvalgt fra: GCCACCGAGCCGAAUAUACC SEQ ID NO: 11; AUAUAUAUAUAUAUAUAUAU SEQ ID NO:12; UUAUUAUUAUUAUUAUUAUU SEQ IDNO:13; AAUAAUAAUAAUAAUAAUAA SEQ ID NO:16; AAAUAAAUAAAUAAAUAAAU SEQ ID NO:17; AAAAUAAAAUAAAAUAAAAU SEQ ID NO:18; CUACUACUACUACUACUACU SEQ ID NO:24; UUAUUAU SEQ ID NO:30; UAUAUAU SEQ ID NO:33; CCGAGCCGCAUAUCCC SEQ ID NO:36; CCGAGCCGCUAUACCC SEQ ID NO:37; CCGAGCCAUAUAUCCC SEQ ID NO:38; CCGAGCCAUAUAUAUC SEQ ID NO:39; CCGAGCCGAAUAACCC SEQ ID NO:40; CCGAGCCGCAUAACCC SEQ ID NO:41; CCGAGCCGAAUACCCC SEQ ID NO:42; CCGAGCCGCCUAACCC SEQ ID NO:43; CCGAGCCGAAUCCCCC SEQ ID NO:44; CCGAGCCGCAUACCCC SEQ ID NO:45; CCGAGCCGCAUCCCCC SEQ ID NO:46; CCGAGCCGCCUACCCC SEQ ID NO:47; CCGAGCCGCAUUACCC SEQ ID NO:48; CCGAGCCGCUAUCCCC SEQ ID NO:55; CCGAGCCGAAUGUACC SEQ ID NO:63; CCGAGCCGAUAUUACC SEQ ID NO:65; CCGAGCCGAAGGUACC SEQ ID NO:82; CCGAGCCGAAGGUGCC SEQ ID NO:83; CCGAGCCGAAGCUCCC SEQ ID NO:84; CCGAGCCGAAGAUACC SEQ ID NO:85; CCGAGCCGAAGCUACC SEQ ID NO:87; og CCGAGCCGAAGCUGCC SEQ ID NO:88; hvor ORN'et eventuelt indeholder mindst en backbone-modifikation. 4.0RN ifølge krav 3, yderligere omfattende en farmaceutisk acceptabel bærer. 5.0RN ifølge krav 3, hvor ORN er komplekseret til N-[1-(2,3-dioleoyloxy)propyl]-N,N,Ntrimethylammoniummethyl-sulfat (DOTAP).
6. RNA-oligonukleotid (ORN) ifølge krav 3, hvor oligonukleotidet desuden omfatter internukleotidphosphorothioat-bindinger.
7. Anvendelse af en sammensætning af et ORN ifølge et af kravene 3-6 ved fremstilling af et medikament til behandling af en immunsystemdeficiens, en infektion, en autoimmun sygdom, cancer, en allergisk tilstand, astma, astma forværret af en virusinfektion eller til anvendelse ved behandling af luftvejsremodellering.
8. ORN ifølge et af kravene 3-6 til anvendelse ved behandling af en immunsystemdeficiens, en infektion, en autoimmun sygdom, cancer, en allergisk tilstand, astma, astma forværret af virusinfektion eller til anvendelse ved be- handling af luftvejsremodellering.
9. Fremgangsmåde til nedregulering af immunsuppressive CD4+ regulator (Treg)-celler, hvilken fremgangsmåde omfatter: at bringe in vitro en CD4+ Treg-celle i kontakt med en sammensætning omfattende et ORN ifølge et af kravene 3-6 i en virksom mængde til reduktion af en hæmmende effekt af CD4+ Treg-cellen.
10.ORN ifølge et af kravene 3-6 til anvendelse som et medikament.
11. ORN ifølge et af kravene 3-6 og krav 10 til anvendelse ved stimulering eller modulering af en immunreaktion.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73952905P | 2005-11-25 | 2005-11-25 | |
US77898906P | 2006-03-03 | 2006-03-03 | |
PCT/US2006/045183 WO2007062107A2 (en) | 2005-11-25 | 2006-11-22 | Immunostimulatory oligoribonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1957647T3 true DK1957647T3 (da) | 2015-04-07 |
Family
ID=37946151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06838257T DK1957647T3 (da) | 2005-11-25 | 2006-11-22 | Immunstimulerende oligoribonukleotider |
Country Status (16)
Country | Link |
---|---|
US (3) | US7662949B2 (da) |
EP (2) | EP2883957A1 (da) |
JP (1) | JP4538522B2 (da) |
KR (1) | KR20080072934A (da) |
CN (1) | CN102517292B (da) |
AU (2) | AU2006318464B2 (da) |
BR (2) | BRPI0622298A8 (da) |
CA (1) | CA2630738C (da) |
DK (1) | DK1957647T3 (da) |
ES (1) | ES2536103T3 (da) |
HK (1) | HK1210212A1 (da) |
PL (1) | PL1957647T3 (da) |
PT (1) | PT1957647E (da) |
SI (1) | SI1957647T1 (da) |
TW (1) | TW200738877A (da) |
WO (1) | WO2007062107A2 (da) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
NZ508650A (en) * | 1998-05-14 | 2003-05-30 | Coley Pharm Gmbh | Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification |
DK1077722T3 (da) * | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
DE60139689D1 (de) * | 2000-06-22 | 2009-10-08 | Univ Iowa Res Found | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. |
NZ531194A (en) | 2001-08-17 | 2007-02-23 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
US8153141B2 (en) * | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
EA008777B1 (ru) | 2002-10-29 | 2007-08-31 | Коли Фармасьютикал Груп, Лтд. | Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c |
JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
AU2004257149A1 (en) * | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
JP4989225B2 (ja) * | 2003-09-25 | 2012-08-01 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 核酸親油性接合体 |
UA88457C2 (ru) | 2003-10-30 | 2009-10-26 | Коли Фармасьютикал Гмбх | Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050256073A1 (en) * | 2004-02-19 | 2005-11-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral RNA oligonucleotides |
EP1716234B1 (de) * | 2004-02-20 | 2013-10-02 | Mologen AG | Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren |
KR100958505B1 (ko) * | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
BRPI0610449A2 (pt) * | 2005-04-08 | 2012-01-10 | Coley Pharm Group Inc | métodos para tratar asma exarcebada por doença infecciosa |
EP1904530A2 (en) * | 2005-07-07 | 2008-04-02 | Coley Pharmaceutical Group, Inc. | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
KR20080047463A (ko) * | 2005-09-16 | 2008-05-28 | 콜리 파마슈티칼 게엠베하 | 뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(sirna)의 면역자극 특성의 조절 |
BRPI0616235A2 (pt) * | 2005-09-16 | 2011-06-14 | Coley Pharm Gmbh | acido ribonuclÉico monofilamentado imunoestimulante com cadeia principal de fosfodiÉster |
CN102517292B (zh) | 2005-11-25 | 2014-12-24 | 佐蒂斯比利时股份有限公司 | 免疫刺激性寡核糖核苷酸 |
AU2007235231B2 (en) | 2006-04-07 | 2012-04-12 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 |
MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
BRPI0719445A2 (pt) * | 2006-09-27 | 2013-12-10 | Coley Pharm Group Inc | Composições de ligandos de tlr e antivirais. |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
ES2544484T3 (es) * | 2007-05-18 | 2015-08-31 | Adiutide Pharmaceuticals Gmbh | Análogos de oligonucleótidos modificados con fosfato con actividad inmunoestimulante |
AU2008279509B2 (en) | 2007-07-09 | 2011-07-21 | Idera Pharmaceuticals, Inc. | Stabilized immune modulatory RNA (SIMRA) compounds |
BRPI0814260B8 (pt) * | 2007-08-13 | 2021-05-25 | Coley Pharm Gmbh | composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero |
WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
PT2176408E (pt) | 2008-01-31 | 2015-04-23 | Curevac Gmbh | Ácidos nucleicos compreendendo a fórmula (nuglxmgnnv)a e os seus derivados como agentes/adjuvantes imunoestimuladores |
US10383887B2 (en) * | 2008-02-20 | 2019-08-20 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
KR101023194B1 (ko) * | 2009-02-25 | 2011-03-18 | 사회복지법인 삼성생명공익재단 | 아토피 피부염 진단용 마커 및 그의 용도 |
CA2744346A1 (en) * | 2009-03-17 | 2010-09-23 | Gunther Hartmann | Tlr 7 ligand and uses thereof |
CA3033133C (en) | 2009-03-25 | 2021-11-09 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
WO2010138192A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Nanocarriers possessing components with different rates of release |
JP5854559B2 (ja) | 2009-07-06 | 2016-02-09 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 小胞を調製する方法及びこれから製造される製剤 |
CA2803282C (en) | 2009-07-06 | 2018-05-01 | David E. Anderson | Methods for preparing vesicles and formulations produced therefrom |
US20110110965A1 (en) | 2009-08-26 | 2011-05-12 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011061568A1 (en) * | 2009-11-22 | 2011-05-26 | Azure Vault Ltd. | Automatic chemical assay classification |
CA2798994A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
BR112013000394B8 (pt) | 2010-07-06 | 2022-01-18 | Variation Biotechnologies Inc | Composição imunogênica, uso da mesma e método para preparar a referida composição |
EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
CN107012149A (zh) * | 2010-11-19 | 2017-08-04 | 艾德拉药物股份有限公司 | 调控基于toll‑样受体的免疫应答的免疫调节寡核苷酸(iro)化合物 |
US20120177701A1 (en) * | 2010-12-31 | 2012-07-12 | Selecta Biosciences, Inc. | Compositions comprising immunostimulatory nucleic acids and related methods |
BR112013017939B1 (pt) | 2011-01-13 | 2022-11-16 | Variation Biotechnologies Inc | Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma |
WO2013009586A1 (en) * | 2011-07-08 | 2013-01-17 | The Research Foundation Of State University Of New York | Topical minocycline ointment for suppression of allergic skin responses |
EP2736537A4 (en) | 2011-07-29 | 2015-04-15 | Selecta Biosciences Inc | SYNTHETIC NANOTRANSPORTERS FOR THE PRODUCTION OF HUMOROUS AND CYTOTOXIC T-LYMPHOCY (CTL) IMMUNE REACTIONS |
US9636414B2 (en) | 2011-12-15 | 2017-05-02 | Biontech Ag | Particles comprising single stranded RNA and double stranded RNA for immunomodulation |
US10172960B2 (en) | 2011-12-15 | 2019-01-08 | Biontech Ag | Particles comprising single stranded RNA and double stranded RNA for immunomodulation |
EP2802353A4 (en) | 2012-01-12 | 2015-12-02 | Variation Biotechnologies Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS |
CA2894467A1 (en) | 2012-01-27 | 2013-08-01 | Variation Biotechnologies Inc. | Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
US9228184B2 (en) | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
KR20150127206A (ko) | 2013-03-14 | 2015-11-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 나노입자-기재 조성물 |
MX369469B (es) | 2013-08-21 | 2019-11-08 | Curevac Ag | Vacuna contra el virus respiratorio sincitial. |
EP3110401A4 (en) | 2014-02-25 | 2017-10-25 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
EA201692512A1 (ru) | 2014-06-25 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
CN105193836A (zh) * | 2015-09-11 | 2015-12-30 | 陶烈晖 | 外用补充核苷酸的方法和制剂 |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
RU2713167C1 (ru) * | 2018-11-21 | 2020-02-04 | Артур Витович Жиурис | Способ лечения гепатитов и состав для его осуществления |
EP4104830A1 (en) | 2021-06-16 | 2022-12-21 | Burghardt Wittig | Sequential innate and adaptive immune modulation for cancer treatment |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
JPH0669953B2 (ja) | 1985-08-16 | 1994-09-07 | 日産化学工業株式会社 | 脳脊髄系神経栄養剤 |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US4950652A (en) | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
ATE226250T1 (de) * | 1992-04-30 | 2002-11-15 | Innogenetics Nv | Polypeptide und peptide dafür kodierende nukleinsaüre und ihre verwendung im zusammenhang mit tumortherapie, entzündung oder immunology |
US6342484B1 (en) | 1993-06-30 | 2002-01-29 | Board Of Regents, The University Of Texas Systems | Method and compositions for promotion of wound treatment |
AU7319994A (en) | 1993-06-30 | 1995-01-24 | Board Of Regents, The University Of Texas System | Nucleotide preparation and uses thereof in wound healing |
US5602109A (en) | 1994-01-10 | 1997-02-11 | Abbott Laboratories | Method to enhance the immune system of a human |
US5488039A (en) | 1994-01-10 | 1996-01-30 | Abbott Laboratories | Method for the production of an enteral formula containing ribo-nucleotides |
US5700590A (en) | 1994-01-10 | 1997-12-23 | Abbott Laboratories | Nutritional formula with ribo-nucleotides |
US5492899A (en) | 1994-01-10 | 1996-02-20 | Abbott Laboratories | Infant nutritional formula with ribo-nucleotides |
AU710504B2 (en) | 1994-03-15 | 1999-09-23 | Brown University Research Foundation | Polymeric gene delivery system |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20030050263A1 (en) | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5612060A (en) | 1995-05-25 | 1997-03-18 | Alexander; J. Wesley | Enhancement of transplant graft survival through nutritional immunomodulation and immunosuppressive therapy |
WO1997003702A1 (en) | 1995-07-21 | 1997-02-06 | Brown University Research Foundation | A method for gene therapy using nucleic acid loaded polymeric microparticles |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
FR2750435B1 (fr) * | 1996-06-27 | 1998-08-28 | Appligene Oncor | Procede de formation de complexes d'hybridation dont la stabilite depend peu de la composition en base des deux molecules d'acides nucleiques hybridees |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
KR20010012770A (ko) * | 1997-05-22 | 2001-02-26 | 세파론, 인코포레이티드 | 비타민 d 유사체 및 그 뉴런 효과 |
EP1009440B1 (en) | 1997-07-03 | 2008-09-17 | MacFarlane, Donald E. | Method for inhibiting immunostimulatory dna associated responses |
JP2002510644A (ja) | 1998-04-03 | 2002-04-09 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物 |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
NZ508650A (en) | 1998-05-14 | 2003-05-30 | Coley Pharm Gmbh | Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification |
DK1077722T3 (da) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
EP1100807A1 (en) | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
AU777225B2 (en) | 1998-09-03 | 2004-10-07 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
EP1177439B1 (en) | 1999-04-29 | 2004-09-08 | Coley Pharmaceutical GmbH | Screening for immunostimulatory dna functional modifiers |
EP1377554A1 (en) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
UA77152C2 (en) | 1999-09-25 | 2006-11-15 | Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma | |
DE60029460T3 (de) | 1999-09-27 | 2011-02-10 | Coley Pharmaceutical Gmbh | Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
JP2003514791A (ja) | 1999-11-02 | 2003-04-22 | カイロン コーポレイション | 二本鎖RNAレセプター(dsRNA−R)およびそれに関連する方法 |
WO2001045750A1 (en) | 1999-12-21 | 2001-06-28 | The Regents Of The University Of California | Method for preventing an anaphylactic reaction |
CA2396871A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US7491805B2 (en) * | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US20040131628A1 (en) | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US7102024B1 (en) * | 2000-08-01 | 2006-09-05 | Schwartz David A | Functional biopolymer modification reagents and uses thereof |
EP1292331A2 (en) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
DE60139689D1 (de) | 2000-06-22 | 2009-10-08 | Univ Iowa Res Found | Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs. |
US20020165178A1 (en) | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
US20020198165A1 (en) | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
US20020091097A1 (en) | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
DK1366077T3 (da) | 2000-09-15 | 2011-09-12 | Coley Pharm Gmbh | Fremgangsmåde til screening i store mængder af CpG-baserede immunoagonister/-antagonister |
DE60134421D1 (de) | 2000-12-08 | 2008-07-24 | Coley Pharmaceuticals Gmbh | Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung |
AU2002248185A1 (en) | 2000-12-14 | 2002-07-16 | Coley Pharmaceutical Group, Inc. | Inhibition of angiogenesis by nucleic acids |
US20030050268A1 (en) | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
AU2002318944A1 (en) | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
NZ531194A (en) | 2001-08-17 | 2007-02-23 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
CA2461315A1 (en) | 2001-10-05 | 2003-04-17 | Coley Pharmaceutical Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
AU2002358616A1 (en) | 2001-12-07 | 2003-06-17 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
CN1694621A (zh) * | 2002-04-04 | 2005-11-09 | 科勒制药股份公司 | 含有g,u的免疫刺激寡核糖核苷酸 |
US8153141B2 (en) | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
WO2003103586A2 (en) | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
WO2004007743A2 (en) | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
WO2004026888A2 (en) | 2002-09-19 | 2004-04-01 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
EA008777B1 (ru) | 2002-10-29 | 2007-08-31 | Коли Фармасьютикал Груп, Лтд. | Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c |
US7790867B2 (en) * | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
WO2004087203A2 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
EP1631687A2 (en) | 2003-04-22 | 2006-03-08 | Coley Pharmaceutical GmbH | Methods and products for identification and assessment of tlr ligands |
AU2004257149A1 (en) | 2003-06-20 | 2005-01-27 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
US20050013812A1 (en) | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
JP4989225B2 (ja) * | 2003-09-25 | 2012-08-01 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 核酸親油性接合体 |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
UA88457C2 (ru) | 2003-10-30 | 2009-10-26 | Коли Фармасьютикал Гмбх | Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
US20050256073A1 (en) | 2004-02-19 | 2005-11-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral RNA oligonucleotides |
JP2007531746A (ja) | 2004-04-02 | 2007-11-08 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Il−10応答を誘導するための免疫活性化核酸 |
AU2005326144A1 (en) | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
JP2008506683A (ja) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ, リミテッド | 先天免疫応答を誘導するための方法および組成物 |
KR100958505B1 (ko) | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
US7582744B2 (en) | 2004-08-10 | 2009-09-01 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
EP1819365B1 (en) | 2004-12-09 | 2014-07-02 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
CA2598992A1 (en) | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
AU2006219717B2 (en) | 2005-03-02 | 2009-05-21 | The Secretary Of State For Defence | Pharmaceutical composition |
BRPI0610449A2 (pt) | 2005-04-08 | 2012-01-10 | Coley Pharm Group Inc | métodos para tratar asma exarcebada por doença infecciosa |
WO2006116458A2 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
EP1764107A1 (en) | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
WO2007031322A1 (en) | 2005-09-14 | 2007-03-22 | Gunther Hartmann | Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides |
EA200801045A1 (ru) | 2005-10-12 | 2008-10-30 | Кэнсер Рисерч Текнолоджи Лтд. | Способы и композиции для лечения иммунных нарушений |
CN102517292B (zh) | 2005-11-25 | 2014-12-24 | 佐蒂斯比利时股份有限公司 | 免疫刺激性寡核糖核苷酸 |
WO2007095316A2 (en) | 2006-02-15 | 2007-08-23 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
BRPI0719445A2 (pt) | 2006-09-27 | 2013-12-10 | Coley Pharm Group Inc | Composições de ligandos de tlr e antivirais. |
-
2006
- 2006-11-22 CN CN201110430925.6A patent/CN102517292B/zh active Active
- 2006-11-22 CA CA2630738A patent/CA2630738C/en active Active
- 2006-11-22 KR KR1020087015356A patent/KR20080072934A/ko not_active Application Discontinuation
- 2006-11-22 JP JP2008542433A patent/JP4538522B2/ja active Active
- 2006-11-22 SI SI200631904T patent/SI1957647T1/sl unknown
- 2006-11-22 PT PT68382571T patent/PT1957647E/pt unknown
- 2006-11-22 AU AU2006318464A patent/AU2006318464B2/en active Active
- 2006-11-22 ES ES06838257.1T patent/ES2536103T3/es active Active
- 2006-11-22 US US11/603,978 patent/US7662949B2/en active Active
- 2006-11-22 WO PCT/US2006/045183 patent/WO2007062107A2/en active Application Filing
- 2006-11-22 BR BRPI0622298A patent/BRPI0622298A8/pt not_active Application Discontinuation
- 2006-11-22 DK DK06838257T patent/DK1957647T3/da active
- 2006-11-22 EP EP15150854.6A patent/EP2883957A1/en not_active Withdrawn
- 2006-11-22 EP EP06838257.1A patent/EP1957647B1/en active Active
- 2006-11-22 PL PL06838257T patent/PL1957647T3/pl unknown
- 2006-11-22 BR BRPI0618857-5A patent/BRPI0618857B1/pt active IP Right Grant
- 2006-11-23 TW TW095143354A patent/TW200738877A/zh unknown
-
2009
- 2009-12-09 US US12/633,963 patent/US20100316659A1/en not_active Abandoned
-
2011
- 2011-03-14 US US13/046,871 patent/US8354522B2/en active Active
- 2011-05-11 AU AU2011202189A patent/AU2011202189B2/en active Active
-
2015
- 2015-10-30 HK HK15110758.4A patent/HK1210212A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006318464B2 (en) | 2011-02-17 |
PL1957647T3 (pl) | 2015-07-31 |
WO2007062107A2 (en) | 2007-05-31 |
ES2536103T3 (es) | 2015-05-20 |
US20070142315A1 (en) | 2007-06-21 |
US8354522B2 (en) | 2013-01-15 |
AU2011202189A1 (en) | 2011-06-02 |
CN102517292B (zh) | 2014-12-24 |
AU2006318464A1 (en) | 2007-05-31 |
JP2009517048A (ja) | 2009-04-30 |
BRPI0622298A2 (pt) | 2012-12-11 |
CA2630738A1 (en) | 2007-05-31 |
US7662949B2 (en) | 2010-02-16 |
US20100316659A1 (en) | 2010-12-16 |
TW200738877A (en) | 2007-10-16 |
CA2630738C (en) | 2013-09-03 |
WO2007062107A3 (en) | 2007-07-12 |
PT1957647E (pt) | 2015-06-01 |
BRPI0618857B1 (pt) | 2022-07-19 |
EP1957647B1 (en) | 2015-03-04 |
JP4538522B2 (ja) | 2010-09-08 |
EP1957647A2 (en) | 2008-08-20 |
KR20080072934A (ko) | 2008-08-07 |
BRPI0618857A8 (pt) | 2016-04-05 |
SI1957647T1 (sl) | 2015-04-30 |
CN102517292A (zh) | 2012-06-27 |
BRPI0622298A8 (pt) | 2016-04-05 |
AU2011202189B2 (en) | 2012-05-17 |
BRPI0618857A2 (pt) | 2011-09-13 |
EP2883957A1 (en) | 2015-06-17 |
HK1210212A1 (en) | 2016-04-15 |
US20110206719A1 (en) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1957647T3 (da) | Immunstimulerende oligoribonukleotider | |
US20100144846A1 (en) | Oligoribonucleotides and uses thereof | |
US20060241076A1 (en) | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | |
US8466124B2 (en) | RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles | |
EP1928500A2 (en) | Modulation of tlr-mediated immune responses using adaptor oligonucleotides | |
CA2790802C (en) | Immunostimulatory oligoribonucleotides | |
MX2008006770A (en) | Immunostimulatory oligoribonucleotides |